vs
Apellis Pharmaceuticals, Inc.（APLS）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
LiveRamp Holdings, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$212.2M vs $199.9M），LiveRamp Holdings, Inc.净利率更高（18.8% vs -29.5%，领先48.3%），LiveRamp Holdings, Inc.同比增速更快（8.6% vs -5.9%），过去两年LiveRamp Holdings, Inc.的营收复合增速更高（11.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
APLS vs RAMP — 直观对比
营收规模更大
RAMP
是对方的1.1倍
$199.9M
营收增速更快
RAMP
高出14.5%
-5.9%
净利率更高
RAMP
高出48.3%
-29.5%
两年增速更快
RAMP
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $212.2M |
| 净利润 | $-59.0M | $39.9M |
| 毛利率 | — | 71.9% |
| 营业利润率 | -25.6% | 18.6% |
| 净利率 | -29.5% | 18.8% |
| 营收同比 | -5.9% | 8.6% |
| 净利润同比 | -62.2% | 255.7% |
| 每股收益（稀释后） | $-0.40 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSRAMP
| Q4 25 | $199.9M | $212.2M | ||
| Q3 25 | $458.6M | $199.8M | ||
| Q2 25 | $178.5M | $194.8M | ||
| Q1 25 | $166.8M | $188.7M | ||
| Q4 24 | $212.5M | $195.4M | ||
| Q3 24 | $196.8M | $185.5M | ||
| Q2 24 | $199.7M | $176.0M | ||
| Q1 24 | $172.3M | $171.9M |
净利润APLSRAMP
| Q4 25 | $-59.0M | $39.9M | ||
| Q3 25 | $215.7M | $27.4M | ||
| Q2 25 | $-42.2M | $7.7M | ||
| Q1 25 | $-92.2M | $-6.3M | ||
| Q4 24 | $-36.4M | $11.2M | ||
| Q3 24 | $-57.4M | $1.7M | ||
| Q2 24 | $-37.7M | $-7.5M | ||
| Q1 24 | $-66.4M | $-5.4M |
毛利率APLSRAMP
| Q4 25 | — | 71.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.1% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 71.9% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | 70.6% | ||
| Q1 24 | — | 72.2% |
营业利润率APLSRAMP
| Q4 25 | -25.6% | 18.6% | ||
| Q3 25 | 48.7% | 10.7% | ||
| Q2 25 | -18.6% | 3.7% | ||
| Q1 25 | -50.0% | -6.1% | ||
| Q4 24 | -12.3% | 7.5% | ||
| Q3 24 | -24.0% | 4.0% | ||
| Q2 24 | -14.7% | -3.0% | ||
| Q1 24 | -36.0% | -8.3% |
净利率APLSRAMP
| Q4 25 | -29.5% | 18.8% | ||
| Q3 25 | 47.0% | 13.7% | ||
| Q2 25 | -23.6% | 4.0% | ||
| Q1 25 | -55.3% | -3.3% | ||
| Q4 24 | -17.1% | 5.7% | ||
| Q3 24 | -29.2% | 0.9% | ||
| Q2 24 | -18.9% | -4.3% | ||
| Q1 24 | -38.5% | -3.1% |
每股收益（稀释后）APLSRAMP
| Q4 25 | $-0.40 | $0.62 | ||
| Q3 25 | $1.67 | $0.42 | ||
| Q2 25 | $-0.33 | $0.12 | ||
| Q1 25 | $-0.74 | $-0.10 | ||
| Q4 24 | $-0.30 | $0.17 | ||
| Q3 24 | $-0.46 | $0.03 | ||
| Q2 24 | $-0.30 | $-0.11 | ||
| Q1 24 | $-0.54 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $403.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $962.3M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSRAMP
| Q4 25 | $466.2M | $403.4M | ||
| Q3 25 | $479.2M | $376.9M | ||
| Q2 25 | $370.0M | $371.1M | ||
| Q1 25 | $358.4M | $420.8M | ||
| Q4 24 | $411.3M | $384.3M | ||
| Q3 24 | $396.9M | $348.4M | ||
| Q2 24 | $360.1M | $342.7M | ||
| Q1 24 | $325.9M | $368.9M |
总债务APLSRAMP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSRAMP
| Q4 25 | $370.1M | $962.3M | ||
| Q3 25 | $401.2M | $943.8M | ||
| Q2 25 | $156.3M | $947.8M | ||
| Q1 25 | $164.2M | $948.9M | ||
| Q4 24 | $228.5M | $957.7M | ||
| Q3 24 | $237.1M | $932.1M | ||
| Q2 24 | $264.3M | $951.9M | ||
| Q1 24 | $266.7M | $949.1M |
总资产APLSRAMP
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | $1.3B | ||
| Q4 24 | $885.1M | $1.3B | ||
| Q3 24 | $901.9M | $1.2B | ||
| Q2 24 | $904.5M | $1.2B | ||
| Q1 24 | $831.9M | $1.2B |
负债/权益比APLSRAMP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSRAMP
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $57.4M | ||
| Q2 25 | $4.4M | $-15.8M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | $45.1M | ||
| Q3 24 | $34.1M | $55.6M | ||
| Q2 24 | $-8.3M | $-9.3M | ||
| Q1 24 | $-133.0M | — |
自由现金流APLSRAMP
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $56.8M | ||
| Q2 25 | $4.4M | $-16.2M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $44.8M | ||
| Q3 24 | — | $55.4M | ||
| Q2 24 | $-8.4M | $-9.6M | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSRAMP
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 28.4% | ||
| Q2 25 | 2.5% | -8.3% | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 22.9% | ||
| Q3 24 | — | 29.8% | ||
| Q2 24 | -4.2% | -5.4% | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSRAMP
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 1.0% |
现金转化率APLSRAMP
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
RAMP
暂无分部数据
